476615-23-3

Basic information

• Product Name: Benzamide, N-[2-(diethylamino)ethyl]-2-methoxy-4-nitro-
• CAS NO: 476615-23-3
• Molecular Formula: C14H21N3O4
• Molecular Weight: 295.338
• Mol File: 476615-23-3.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Benzamide, N-[2-(diethylamino)ethyl]-2-methoxy-4-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzamide, N-[2-(diethylamino)ethyl]-2-methoxy-4-nitro-(476615-23-3)
• EPA Substance Registry System: Benzamide, N-[2-(diethylamino)ethyl]-2-methoxy-4-nitro-(476615-23-3)

Safety Data

• Hazardous Substances Data: 476615-23-3(Hazardous Substances Data)

Upstream product

• 2597-56-0 4-nitro-o-anisic acid 
• 108-00-9 N,N-dimethylethylenediamine 
• 39614-82-9 2-hydroxy-4-nitrobenzoyl chloride 
• 100-36-7 N,N-diethylethylenediamine 
• 39106-79-1 methyl 2-methoxy-4-nitrobenzoate 
• 39787-83-2 2-methoxy-4-nitrobenzoyl chloride 

Downstream Products

• 848771-79-9 N-(2-diethylamino-ethyl)-2-methoxy-4-methylamino-benzamide 
• 3761-48-6 1112JDO 

Relevant articles and documents

Synthesis of N-(2-diethylamino-ethyl)-4-(4-fluoro-benzamido)-2-methoxybenzamide (desiodo-MIP-1145) by coupling technique and its radioiodination: a potential melanoma imaging agent

Radioiodinated MIP-1145, which specifically targets melanin, is an ideal candidate for targeted therapy of melanoma. An analogue of MIP-1145 lacking the iodo-substituent (desiodo-MIP-1145) was synthesized as a labeling precursor in three simple steps. The radioiodination of desiodo-MIP-1145 by iodine-125 was carried out via an electrophilic substitution reaction. An optimization study for the iodination reaction was carried out. The labeled compound was isolated and purified by means of electrophoresis and HPLC. The maximum radiochemical yield, 76%, was obtained with radiochemical purity greater than 99%. The log P value for [125I]MIP-1145 was measured as 4.5.

Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy

This invention relates to new radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy. The radiohalogenated benzamide derivatives according to the invention exhibit novel and especially advantageous properties, in particular with respect to tumor concentration and retardation, liver concentration and blood accumulation. The radiation-therapy doses to be achieved in the tumor, compared to healthy body tissue, are advantageous for the compounds according to the invention.

NOVEL BENZAMIDE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS

Novel compounds of Formula I which modulate MCH activity are disclosed, in which A is a linker, Ar, is an aryl or heteroaryl group; R1 is hydrogen or a lower alkoxy group; Q together with the carbonyl forms an amide group, which is further substituted with an amine group; R5 is hydrogen, halogen atoms, alkoxy groups, hydroxy, alkylamino groups, dialkylamino groups, hydroxylalkyl groups, carboxamido groups, acylamido groups, acyl groups,-CHO, nitrile, alkyl, alkenyl or alkynyl groups,-SCH3, partially or fully fluorinated alkyl, alkoxy or thioalkoxy groups such as-CH2CF3,-CF2CF3,-CF3,-OCF3,-SCF3;-SO2NH2,-SO2NHAlk,-SO2NAlk2,-SO2AIk; R8 is hydrogen, halogen atoms, alkyl, alkenyl or alkynyl groups, cycloalkyl groups, alkylcycloalkyl groups, alkoxy groups, dialkylamino groups,-CONHAIk,-CONAIk2,-NHCO-Alk,-CO-Alk,-SCH3, partially or fully fluorinated alkyl, alkoxy or thioalkoxy groups such as-CH2CF3,-CF2CF3,-CF3,-OCF3,-SCF3; X is H, F, Cl, Br, I,-SCH3, partially or fully fluorinated alkyl, alkoxy or thioalkoxy groups such as-CH2CF3,-CF2CF3,-CF3,-OCF3,-SCF3; OCH3 or lower alkyl or alkenyl group; and which are useful in the treatment or prevention of e.g. obesity, depression, diabetes, bulimia etc.